Roche, Zealand Pharma Obesity Shot Won't Get Credit From Market for Now -- Market Talk

Dow Jones06-16

1323 GMT - Investors will probably give little credit in the near term to an obesity drug candidate that Roche and Zealand Pharma are jointly developing, UBS analysts say in a research note. The obesity market is hungry for medicines that can deliver modest weight loss with a pristine tolerability, which is exactly the profile of so-called amylin drugs like Zealand and Roche's petrelintide, the analysts say. That said, it will take time for the companies to finish clinical development of the drug and rival Eli Lilly has a time advantage with its own amylin product, eloralintide, as well as a proven commercial track record, they add. Zealand shares fall 4.8%, while Roche's fall 0.5%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

June 16, 2026 09:24 ET (13:24 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643750423?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-16 21:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643750423","market":"nz","top_or_hot":-1,"title":"Roche, Zealand Pharma Obesity Shot Won't Get Credit From Market for Now -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1323 GMT - Investors will probably give little credit in the near term to an obesity drug candidate that Roche and Zealand Pharma are jointly developing, UBS analysts say in a research note. The obesity market is hungry for medicines that can deliver modest weight loss with a pristine tolerability, which is exactly the profile of so-called amylin drugs like Zealand and Roche's petrelintide, the analysts say. That said, it will take time for the companies to finish clinical development of the drug and rival Eli Lilly has a time advantage with its own amylin product, eloralintide, as well as a proven commercial track record, they add. Zealand shares fall 4.8%, while Roche's fall 0.5%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 16, 2026 09:24 ET (13:24 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche, Zealand Pharma Obesity Shot Won't Get Credit From Market for Now -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche, Zealand Pharma Obesity Shot Won't Get Credit From Market for Now -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-16 21:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1323 GMT - Investors will probably give little credit in the near term to an obesity drug candidate that Roche and Zealand Pharma are jointly developing, UBS analysts say in a research note. The obesity market is hungry for medicines that can deliver modest weight loss with a pristine tolerability, which is exactly the profile of so-called amylin drugs like Zealand and Roche's petrelintide, the analysts say. That said, it will take time for the companies to finish clinical development of the drug and rival Eli Lilly has a time advantage with its own amylin product, eloralintide, as well as a proven commercial track record, they add. Zealand shares fall 4.8%, while Roche's fall 0.5%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 16, 2026 09:24 ET (13:24 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RHHBY","symbol_name":"罗氏控股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2643750423","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643750423","pubTimestamp":1781616240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1323 GMT - Investors will probably give little credit in the near term to an obesity drug candidate that Roche and Zealand Pharma are jointly developing, UBS analysts say in a research note. The obesity market is hungry for medicines that can deliver modest weight loss with a pristine tolerability, which is exactly the profile of so-called amylin drugs like Zealand and Roche's petrelintide, the analysts say. That said, it will take time for the companies to finish clinical development of the drug and rival Eli Lilly has a time advantage with its own amylin product, eloralintide, as well as a proven commercial track record, they add. Zealand shares fall 4.8%, while Roche's fall 0.5%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RHHBY":"罗氏控股","03165":"华夏欧优股对冲","BK4007":"制药"},"translate_title":"罗氏和新西兰制药公司的肥胖疫苗目前不会获得市场的认可——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHHBY":0.9,"03165":0.6},"content_text":"1323 GMT - Investors will probably give little credit in the near term to an obesity drug candidate that Roche and Zealand Pharma are jointly developing, UBS analysts say in a research note. The obesity market is hungry for medicines that can deliver modest weight loss with a pristine tolerability, which is exactly the profile of so-called amylin drugs like Zealand and Roche's petrelintide, the analysts say. That said, it will take time for the companies to finish clinical development of the drug and rival Eli Lilly has a time advantage with its own amylin product, eloralintide, as well as a proven commercial track record, they add. Zealand shares fall 4.8%, while Roche's fall 0.5%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 16, 2026 09:24 ET (13:24 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643750423","isCrawlerRequest":true}